PR Positive: 155 Real Stories

155 stories match PR positive. 133 of them mention surgery.

Cancer Stories

A patient, who was diagnosed with Stage I Invasive Ductal CarcinomaBreast Cancer

Stage 1 invasive ductal breast cancer: nipple-preserving mastectomy with reconstruction

Patient Info: Anonymized, Female, 60s | Stage I

Biomarkers: ER-positive; PR-positive; HER2-negative; Ki-67 28%

No signs of recurrence 20 months after nipple-preserving mastectomy, sentinel node biopsy, immediate reconstruction, adjuvant chemotherapy, and endocrine therapy for ER-positive, PR-positive, HER2-negative invasive ductal breast cancer.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage 4 breast cancer: ongoing treatment with multi-line chemotherapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Initial tumor: hormone receptor-negative; HER2 2+. 2011 recurrence: ER 10%; PR 70%; HER2 2+.

Metastatic Site: pleura/pleural effusion; lung

Metastatic breast cancer with malignant pleural effusion achieved complete response after chemotherapy and long-term endocrine therapy; PET-CT in October 2023 still showed complete response, with ongoing cardiac and bone-health management.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Right-Sided Ductal Carcinoma in Situ Before a Second Breast Cancer

Patient Info: Anonymized, female, 60s

Biomarkers: ER-positive; PR-positive; HER2 1+

A woman treated for right-sided ductal carcinoma in situ in 2018 later developed a separate invasive cancer in the opposite breast.

PubMed Central
OutcomeNot reported
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage 4 luminal A breast cancer: tumor regression on hormone therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: skin, soft tissue, lungs

Metastatic Luminal A breast cancer involving skin/soft tissue and lungs showed regressing tumors and stable lung metastasis after 3 months of anti-hormone therapy plus capecitabine; longer-term control was not reported.

PubMed Central
OutcomeLiving With Cancer
Kim, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Invasive Lobular Carcinoma: Kim's Survivor Story

Patient Info: Kim, Female

Biomarkers: ER 99% positive; PR 85% positive; HER2-negative

Kim’s ER-positive, PR-positive, HER2-negative ILC responded strongly to Zoladex and Letrozole before skin-sparing mastectomy, with 90% tumor necrosis, clear margins, no lymph node spread, and confirmation that she was cancer-free.

Lobular Breast Cancer Alliance
OutcomeCancer-Free / NED
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

ER/PR-positive invasive mucinous breast cancer: mastectomy, DIEP reconstruction, and tamoxifen

Patient Info: Anonymized, trans woman, 50s

Biomarkers: ER 100% positive; PR 100% positive; HER2-negative; 19-gene hereditary cancer panel negative

As of May 2024, she was 1 year after bilateral DIEP free-flap reconstruction, satisfied with the cosmetic result, taking tamoxifen for recurrence-risk reduction, and planning nipple reconstruction; no recurrence status beyond the postoperative course was stated.

PubMed Central
OutcomeCare Ongoing
Allison, who was diagnosed with Stage I Breast CancerBreast Cancer

Stage I HR-Positive Breast Cancer: Allison's Survivor Story

Patient Info: Allison Tierney, Female | Stage I

Biomarkers: ER-positive; PR-positive; HER2-positive

As of May 2024, Allison had recently completed her cancer treatment journey and reported successful hair preservation with cold capping during Taxol chemotherapy.

The Patient Story
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Invasive lobular breast cancer with isolated scalp metastasis: excision and endocrine therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Original breast tumor: ER-positive; PR-positive; scalp metastasis: CK7-positive; ER-positive; GCDFP-15 partially positive

Metastatic Site: scalp/skin

As of April 2024, she had no signs of recurrence in the breast or scalp and no distant metastasis after excision of the isolated scalp metastasis while continuing anastrozole.

PubMed Central
OutcomeCancer-Free / NED
Allison, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: Allison's Patient Story

Patient Info: Allison Tierney, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; CHEK2 mutation; BRCA1/2 negative

As of March 2024, Allison had completed Taxol and Herceptin treatment, was on tamoxifen planned for 10 years, and had moved to 6-month oncology follow-up. No metastatic disease or recurrence was reported.

YouTube — The Patient Story
OutcomeCare Ongoing
Dorian, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: Dorian's Survivor Story

Patient Info: Dorian de Salvo, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of March 2024, Dorian had a complete response to TCHP chemotherapy, clear surgical margins, and no lymph-node involvement after surgery, with radiation completed and additional care still expected for several months.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Metastatic hormone receptor-positive breast cancer with paraneoplastic eosinophilic fasciitis

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: ER-positive; PR-positive; eosinophilia during paraneoplastic eosinophilic fasciitis flare

Metastatic Site: pelvis

As of February 2024, paraneoplastic eosinophilic fasciitis had remitted after prednisone plus systemic breast-cancer therapy, and 6-month follow-up showed no further skin recurrence or cancer progression.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Male Invasive Lobular Breast Cancer With a Pathogenic PALB2 Variant

Patient Info: Anonymized, male, 40s

Biomarkers: ER-positive; PR-positive; HER2 not amplified; pathogenic PALB2 variant

He was disease-free at 1-year follow-up after mastectomy, chemotherapy, and radiotherapy.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Breast CancerBreast Cancer

Aggressive breast cancer presenting with severe skin infection

Patient Info: Anonymized, Female

Biomarkers: ER 99% positive; PR 99% positive; HER2 1+ / negative; Ki-67 3%; grade 2; 3 interpectoral lymph nodes negative; later axillary-node biopsy benign

She recovered from sepsis and surgery, had no distant metastases and a benign axillary-node biopsy, and was receiving adjuvant radiation with anastrozole ongoing.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage I Breast CancerBreast Cancer

A Breast Cancer Survivor Later Diagnosed With a Separate Metastatic Cancer Affecting Both Retinas

Patient Info: Anonymized, Female, 60s | Stage I

Biomarkers: ER-positive, PR-positive, HER2-negative

Her last breast-cancer follow-up showed no evidence of disease after 5 years of endocrine therapy. She later developed a separate widely metastatic cancer favored to be gastrointestinal or pancreaticobiliary in origin and died after choosing hospice.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage I Breast CancerBreast Cancer

Five Years Without Breast Cancer Recurrence Despite a Markedly Elevated CA 15-3

Patient Info: Anonymized, female, 70+ | Stage I

Biomarkers: ER-positive, PR-positive, HER2-positive

Five years after her Stage I breast-cancer diagnosis, breast imaging and systemic evaluation showed no evidence of recurrence. The markedly elevated CA 15-3 was traced to a separate renal tumor and normalized after nephrectomy.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Breast Tumor Disappears on Imaging During Treatment for Multiple Myeloma

Patient Info: Anonymized, female, 60s

Biomarkers: ER-positive, PR-positive, HER2-negative

The breast lesion showed a complete radiologic response before planned surgery, and there was no evidence of breast-cancer relapse or progression through 2022, about 5 years after diagnosis.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Male breast cancer in both breasts linked to Klinefelter syndrome, initially missed

Patient Info: Anonymized, Male | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; Klinefelter syndrome

Metastatic Site: spine / bone

With advanced metastatic disease and an estimated prognosis of weeks or less, care focused on symptom relief under the palliative-care team.

PubMed Central
OutcomeEnd of Life / Hospice
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Stage III Breast Cancer Linked to Paraneoplastic Neuromyelitis Optica

Patient Info: Anonymized, female, 50s | Stage III

Biomarkers: ER-positive, PR-positive, HER2-negative; tumor AQP4 expression

A 51-year-old woman with Stage III hormone-receptor-positive breast cancer developed a rare paraneoplastic neurologic disorder that caused severe vomiting and spinal-cord symptoms.

PubMed Central
OutcomeNot reported
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Metastatic Breast Cancer Treatment Complicated by a Supplement–Drug Interaction

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-negative

Metastatic Site: bones

She resumed ribociclib with letrozole after the supplement was discontinued and the treatment-related neutropenia improved enough to restart therapy.

PubMed Central
OutcomeCare Ongoing